latest news releases from the newsroom
Empire Film Group, Inc.
New Productions, Acquisitions for Empire Film Group Drive Impressive 2009 Release Slate
MALIBU, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- With a combined slate of more than forty new releases, Empire Film Group, Inc. (Pink Sheets:EFGU) (http://www.empirefilmgroup.com) is positioned to rapidly ascend to the top tier of independent studios by the end of 2009, reports CEO Dean Hamilton-Bornstein. With eight theatrical films, thirty direct-to-video titles and six new release books from the company's Hannover House publishing division, Empire anticipates revenues in 2009 that would place the company in third position among all domestic independent distributors, subordinate only to Lionsgate and Summit Releasing for total market share.
Infinity Pharmaceuticals, Inc.
Infinity Announces 2009 and Long-Term Goals, Building On 2008 Success
CAMBRIDGE, Mass., Jan. 12, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reported on its 2008 R&D and business progress, announced its key 2009 objectives, and introduced its I4 2012 goals. Infinity's I4 2012 goals are the four major strategic objectives the company anticipates achieving by the end of 2012.
MediciNova Reports Interim Phase II Data From MN-221 Emergency Department Study
SAN DIEGO, Jan. 12, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced interim results from two planned reviews of the unaudited data for its MN-221-CL-006 Phase II study, which remains ongoing. These reviews included data from a total of 18 (eight treated with standard care only and ten treated with MN-221 plus standard care) of 36 planned patients with severe, acute exacerbations of asthma treated in emergency departments. All patients received standardized care consisting of inhaled albuterol, ipratropium and oral steroid treatment. No safety concerns with adding MN-221 to standardized care were identified in these reviews. The hospitalization rate among patients treated with standardized care only was 50 percent (four of eight), the anticipated rate, compared to a hospitalization rate of 10 percent (one of ten) among patients receiving MN-221 plus standardized care. All hospitalizations were due to asthma exacerbations which were judged to be unrelated to study medication and therefore do not raise safety concerns for adding MN-221 to standardized care. Improvement in pulmonary function measured in FEV1 (forced expiratory volume in 1 second) and decreased symptoms of difficulty breathing on the Modified Borg Dyspnea Index Scale, a clinical rating scale for shortness of breath, were observed in both treatment groups. Improvement in FEV1 values generally appeared to be greater for patients receiving MN221 in addition to standardized treatment. As specified in the protocol for the MN-221-CL-006 study, no inferential statistics (i.e., p-values) will be calculated for this study.
SmallCap Sentinel: The Lean and Mean of the Energy Beverage Market
IRVINE, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- On a strategic basis, big companies are often invested in protecting their market share and expanding from a large base. This leaves small market opportunities to be developed by companies that can identify and grow 'under the radar' market niches. If the 'undiscovered niches' grow by leaps and bounds then shareholders in these equities can potentially reap large returns.